Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Crocin total glycoside is a botanical extract comprising a mixture of water-soluble carotenoid glycosides, primarily derived from *Crocus sativus* (saffron) or *Gardenia jasminoides*. It is currently under clinical investigation by The First Affiliated Hospital of Anhui Medical University for the treatment of liver cirrhosis. The therapeutic potential of crocin total glycoside is attributed to its potent antioxidant, anti-inflammatory, and anti-fibrotic activities. Mechanistically, it is thought to inhibit the activation of hepatic stellate cells and modulate signaling pathways such as TGF-β1/Smad and NF-κB, thereby reducing collagen deposition and liver stiffness. In clinical trials, it is administered as an oral tablet to evaluate its impact on liver function and elastography parameters.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on crocin total glycoside.